Respiratory syncytial virus
Respiratory syncytial virus (RSV) is a major human respiratory pathogen and a frequent cause of lower respiratory tract disease, especially in infants, older adults, and people with chronic medical conditions or other vulnerabilities.
Respiratory syncytial virus (RSV) is a major human respiratory pathogen and a frequent cause of lower respiratory tract disease, especially in infants, older adults, and people with chronic medical conditions or other vulnerabilities. In biomedical research and clinical practice, RSV is studied both as a disease-causing virus and as a target for prevention strategies, including respiratory syncytial virus vaccination, maternal immunization, and passive immunization approaches such as nirsevimab and palivizumab. RSV has also been examined alongside related infectious disease contexts such as COVID-19 and other respiratory virus surveillance frameworks, reflecting its continuing public health importance.
Biologically, RSV is used as a target for antiviral discovery, immune-response studies, and vaccine design. Recent work has investigated small-molecule cyclophilin inhibitors, herbal-derived compounds, and immunomodulatory pathways for anti-RSV activity, while other studies have focused on antibody durability after vaccination in pregnant/postpartum individuals and older adults. In addition, RSV is central to evaluation of newer vaccine platforms such as RSVpreF vaccine and mRNA-1345, as well as health-economic analyses of vaccination in adults at elevated risk.
Where the papers sit
11 papers from the last 6 months study respiratory syncytial virus directly · updated from PubMed 12 Nov 2026
Study type 0 clinical trials · 2 observational · 3 human data · 6 preclinical
Themes 3 themes
-
Antiviral Discovery and Combination Therapy
Antiviral discovery remains largely preclinical, spanning natural products, cyclophilin inhibitors, repurposed drugs and delivery lipids. Studies repeatedly measure RSV activity through inhibitory concentrations and cell-based cytotoxicity. Combination therapy is being explored to broaden antiviral coverage or improve potency. The main open questions are in vivo efficacy, safety and whether these candidates outperform established agents such as ribavirin.
6 papers · 54.5%
-
Maternal RSV Vaccine Acceptance
Maternal RSV vaccination is moving toward implementation shaped by pregnant women’s confidence, communication and perceived responsibility. Vaccine hesitancy recurs alongside practical constraints and uncertainty about infant monoclonal antibodies. The 5C framework is used to identify confidence, constraints and collective responsibility that may affect uptake. National prioritization work links acceptance to broader decisions about introducing maternal vaccination within immunization programs.
3 papers · 27.3%
-
RSV Vaccination Cost Effectiveness
RSVpreF vaccination is being evaluated as a way to prevent illness and reduce emergency department use in older adults. Economic models focus on high-risk adults and compare vaccination costs with avoided respiratory tract disease and healthcare utilization. German analyses extend this assessment to country-specific costs and outcomes. The central unresolved issue is which adult risk groups and program designs provide sufficient value for routine vaccination.
2 papers · 18.2%
Papers
The 11 papers from the last 6 months that study respiratory syncytial virus directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Antiviral Discovery and Combination Therapy (6)
- In Vitro Evaluation of Repurposed Antivirals and Their Combinations Against Respiratory Syncytial Virus and Human Parainfluenza Virus Type 2: Evidence of Ribavirin-Oseltamivir Synergy. Journal of medical virology · 28 Oct 2026 PMID 42949224
- Cholesterol Analogs and Vitamin-Conjugated Ionizable Lipids Enhance Lipid Nanoparticle Delivery for In Vitro and In Vivo Applications. ACS applied materials & interfaces · 13 Aug 2026 PMID 42587484
- Optimization of the antiviral spectrum of cyclophilin inhibitors targeting respiratory viruses. Antimicrobial agents and chemotherapy · 17 Jul 2026 PMID 42467054
- Complex phloroglucinols from glandular hairs of Mallotus philippensis and their antiviral activities. Bioorganic chemistry · 27 Jun 2026 PMID 42364380
- The anti-respiratory syncytial virus activity of biochemicals from Pyrola incarnata. Antiviral research · 26 Jun 2026 PMID 42362061
- Natural AhR ligands: A novel approach to dynamic immune regulation in viral infections. Phytomedicine : international journal of phytotherapy and phytopharmacology · 21 May 2026 PMID 42166972
Maternal RSV Vaccine Acceptance (3)
- 5C psychological antecedents of vaccine hesitancy toward maternal RSV vaccines and infant monoclonal antibodies among pregnant and postpartum women and their partners in China: A multicenter, dyadic survey design, cross-sectional study. Human vaccines & immunotherapeutics · 9 Sept 2026 PMID 42714313
- Prioritizing the introduction of new vaccine in Tanzania (2026-2030): a multi-criteria decision analysis by the Tanzania immunization technical advisory group. Vaccine · 31 Jul 2026 PMID 42537288
- Maternal respiratory syncytial virus (RSV) vaccine perceptions amongst pregnant women and mothers of infants and toddlers in England: a qualitative study. Vaccine · 24 Jul 2026 PMID 42497669
RSV Vaccination Cost Effectiveness (2)
- Clinical and economic impact of bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccination in older adults: a cost-effectiveness analysis for Chile. Expert review of vaccines · 12 Sept 2026 PMID 42728842
- Cost-effectiveness of RSVpreF for the prevention of respiratory syncytial virus illness among high-risk adults in Germany. Expert review of vaccines · 31 Jul 2026 PMID 42535735
By study type
Observational studies and case reports (2)
- 5C psychological antecedents of vaccine hesitancy toward maternal RSV vaccines and infant monoclonal antibodies among pregnant and postpartum women and their partners in China: A multicenter, dyadic survey design, cross-sectional study. Human vaccines & immunotherapeutics · 9 Sept 2026 PMID 42714313
- Cost-effectiveness of RSVpreF for the prevention of respiratory syncytial virus illness among high-risk adults in Germany. Expert review of vaccines · 31 Jul 2026 PMID 42535735
Human data, design not indexed (3)
- Clinical and economic impact of bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccination in older adults: a cost-effectiveness analysis for Chile. Expert review of vaccines · 12 Sept 2026 PMID 42728842
- Prioritizing the introduction of new vaccine in Tanzania (2026-2030): a multi-criteria decision analysis by the Tanzania immunization technical advisory group. Vaccine · 31 Jul 2026 PMID 42537288
- Maternal respiratory syncytial virus (RSV) vaccine perceptions amongst pregnant women and mothers of infants and toddlers in England: a qualitative study. Vaccine · 24 Jul 2026 PMID 42497669
Preclinical: animal, cell and lab studies (6)
- In Vitro Evaluation of Repurposed Antivirals and Their Combinations Against Respiratory Syncytial Virus and Human Parainfluenza Virus Type 2: Evidence of Ribavirin-Oseltamivir Synergy. Journal of medical virology · 28 Oct 2026 PMID 42949224
- Cholesterol Analogs and Vitamin-Conjugated Ionizable Lipids Enhance Lipid Nanoparticle Delivery for In Vitro and In Vivo Applications. ACS applied materials & interfaces · 13 Aug 2026 PMID 42587484
- Optimization of the antiviral spectrum of cyclophilin inhibitors targeting respiratory viruses. Antimicrobial agents and chemotherapy · 17 Jul 2026 PMID 42467054
- Complex phloroglucinols from glandular hairs of Mallotus philippensis and their antiviral activities. Bioorganic chemistry · 27 Jun 2026 PMID 42364380
- The anti-respiratory syncytial virus activity of biochemicals from Pyrola incarnata. Antiviral research · 26 Jun 2026 PMID 42362061
- Natural AhR ligands: A novel approach to dynamic immune regulation in viral infections. Phytomedicine : international journal of phytotherapy and phytopharmacology · 21 May 2026 PMID 42166972
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-08-06. Last written: 2026-09-14 by GPT. Drafted by language models from published abstracts; not medical advice.